Skip to main content
Back
AZTA logo

Azenta, Inc.

Data quality: 100%
Oversold
AZTA
NASDAQ Healthcare Medical - Instruments & Supplies
$21.31
▲ $0.86 (4.21%)
Mkt Cap: 981.57M
Day Range
$20.10 $21.33
52-Week Range
$19.94 $41.73
Volume
839,025
50D / 200D Avg
$30.65 / $31.45
Prev Close
$20.45

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (627 peers)

Metric Stock Sector Median
P/E -17.6 0.3
P/B 0.6 2.9
ROE % -3.2 3.7
Net Margin % -9.4 3.8
Rev Growth 5Y % 3.7 10.0
D/E 0.1 0.2

Analyst Price Target

Hold
$43.00 +101.8%
Low: $38.00 High: $45.00
Forward P/E
26.0
Forward EPS
$0.79
EPS Growth (est.)
+0.0%
Est. Revenue
620 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.76
$1.73 – $1.80
 740 M 1
FY2029 $1.30
$1.28 – $1.33
 680 M 1
FY2028 $1.29
$1.05 – $1.47
 700 M 4

Key Takeaways

Revenue grew 3.69% annually over 5 years — modest growth
Debt/Equity of 0.06 — conservative balance sheet
Generating 38.32M in free cash flow
PEG of 0.39 suggests growth is underpriced
Capital efficient — spends only 5.70% of revenue on capex

Growth

Revenue Growth (5Y)
3.69%
Revenue (1Y)3.55%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-3.19%
ROIC-0.46%
Net Margin-9.39%
Op. Margin-1.90%

Safety

Debt / Equity
0.06
Current Ratio2.98
Interest Coverage0.00

Valuation

P/E Ratio
-17.60
P/B Ratio0.57
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3.55% Revenue Growth (3Y) -5.51%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 3.69% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 593.82M Net Income (TTM) -55.76M
ROE -3.19% ROA -2.71%
Gross Margin 45.52% Operating Margin -1.90%
Net Margin -9.39% Free Cash Flow (TTM) 38.32M
ROIC -0.46% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.06 Current Ratio 2.98
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -17.60 P/B Ratio 0.57
P/S Ratio 1.65 PEG Ratio 0.39
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 981.57M Enterprise Value 812.96M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 593.82M 573.45M 665.07M 555.50M 513.70M
Net Income -55.76M -164.90M -14.26M -428.96M 110.75M
EPS (Diluted) -1.22 -3.09 -0.22 -0.15 -0.39
Gross Profit 270.28M 254.62M 233.26M 230.62M 214.51M
Operating Income -11.27M -29.98M -82.20M -24.02M 3.60M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.06B 2.10B 2.89B 3.72B 1.82B
Total Liabilities 330.70M 331.07M 351.22M 352.74M 494.18M
Shareholders' Equity 1.73B 1.77B 2.53B 3.36B 1.33B
Total Debt 111.17M 70.68M 60.44M 49.23M 94.77M
Cash & Equivalents 279.78M 310.93M 678.91M 658.27M 227.43M
Current Assets 708.34M 832.81M 1.42B 2.46B 777.37M
Current Liabilities 237.67M 204.84M 210.93M 230.55M 345.09M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#494 of 827
37

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026